ISSUE 90 I JANUARY 2020

ACCESS DENIED:

the impact trial

Is NHS England putting patients at risk by restricting access to pre-exposure prophylaxis drugs?

Accessing PrEP in the UK

The burden of endometriosis

China: the new R&D powerhouse

In association with

The burden of endometriosis

The scourge of fake medicines in Africa

Big pharma's presence in China

In association with

02/24/2024 09:36:19
  • Home | Access denied: the Impact trial
  • Scandinavian Health Ltd.
  • In this issue
  • Emirates SkyCargo
  • Contents
  • News
  • Fargo
  • The pharma industry briefing
  • Phoenix Company Insight
  • Phoenix
  • Breast cancer timeline: charting three decades of success
  • PrEP drugs: is the NHS letting down patients at risk of HIV?
  • Swiss WorldCargo
  • Debate: can US pharma be taxed into behaving?
  • LB Bohle Company Insight
  • LB Bohle
  • Can new therapies tackle the burden of endometriosis?
  • The rise of fake medicines in Africa
  • Zenatek
  • Off-the-shelf CAR-T therapy: broadening the reach of precision medicine
  • Nobel Prize 2019: how a breathtaking discovery unlocked new drugs
  • Pfanstiehl Company Insight
  • Pfanstiehl
  • China in 2019: a prime destination for R&D deals
  • The global-local continuum: tips for a joined-up approach to Regulatory & PV out
  • Pharmacovigilance 2.0: reskilling for the digital & data science age
  • Air France KLM Cargo
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Events
  • Next issue
12/18/2019 00:00:00